XBI: Surprise Exit Of A Tough Regulator At The FDA
Seeking Alpha·2025-07-30 11:47
The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up over 20% from the lows in early April, despite events since that should have signaled a tougher regulatory environment at the US Food and Drug Administration (FDA). On Tuesday, it wasScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we ha ...